Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 268

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Open access
Chen, Leonard N, Suy, Simeng, Uhm, Sunghae, Oermann, Eric K, Ju, Andrew W, Chen, Viola, Hanscom, Heather N, Laing, Sarah, Kim, Joy S, Lei, Siyuan, Batipps, Gerald P, Kowalczyk, Keith, Bandi, Gaurav, Pahira, John, McGeagh, Kevin G, Collins, Brian T, Krishnan, Pranay, Dawson, Nancy A, Taylor, Kathryn L, Dritschilo, Anatoly, Lynch, John H, Collins, Sean P · 2013 · Radiation Oncology

Abstract

Background: Stereotactic body radiation therapy (SBRT) delivers fewer high-dose fractions of radiation which may be radiobiologically favorable to conventional low-dose fractions commonly used for prostate cancer radiotherapy. We report our early experience using SBRT for localized prostate cancer. Methods: Patients treated with SBRT from June 2008 to May 2010 at Georgetown University Hospital for localized prostate carcinoma, with or without the use of androgen deprivation therapy (ADT), were included in this retrospective review of data that was prospectively collected in an institutional database. Treatment was delivered using the CyberKnife® with doses of 35 Gy or 36.25 Gy in 5 fractions. Biochemical control was assessed using the Phoenix definition. Toxicities were recorded and scored using the CTCAE v.3. Quality of life was assessed before and after treatment using the Short Form-12 Health Survey (SF-12), the American Urological Association Symptom Score (AUA) and Sexual Health Inventory for Men (SHIM) questionnaires. Late urinary symptom flare was defined as an AUA score ≥ 15 with an increase of ≥ 5 points above baseline six months after the completion of SBRT. Results: One hundred patients (37 low-, 55 intermediate- and 8 high-risk according to the D’Amico classification) at a median age of 69 years (range, 48–90 years) received SBRT, with 11 patients receiving ADT. The median pre-treatment prostate-specific antigen (PSA) was 6.2 ng/ml (range, 1.9-31.6 ng/ml) and the median follow-up was 2.3 years (range, 1.4-3.5 years). At 2 years, median PSA decreased to 0.49 ng/ml (range, 0.1-1.9 ng/ml). Benign PSA bounce occurred in 31% of patients. There was one biochemical failure in a high-risk patient, yielding a two-year actuarial biochemical relapse free survival of 99%. The 2-year actuarial incidence rates of GI and GU toxicity ≥ grade 2 were 1% and 31%, respectively. A median baseline AUA symptom score of 8 significantly increased to 11 at 1 month (p = 0.001), however returned to baseline at 3 months (p = 0.60). Twenty one percent of patients experienced a late transient urinary symptom flare in the first two years following treatment. Of patients who were sexually potent prior to treatment, 79% maintained potency at 2 years post-treatment. Conclusions: SBRT for clinically localized prostate cancer was well tolerated, with an early biochemical response similar to other radiation therapy treatments. Benign PSA bounces were common. Late GI and GU toxicity rates were comparable to conventionally fractionated radiation therapy and brachytherapy. Late urinary symptom flares were observed but the majority resolved with conservative management. A high percentage of men who were potent prior to treatment remained potent two years following treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1748-717x-8-58

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 268

Metadata

Authors
Chen, L. N., Suy, S., Uhm, S., Oermann, E. K., Ju, A. W., Chen, V., Hanscom, H. N., Laing, S., Kim, J. S., Lei, S., Batipps, G. P., Kowalczyk, K., Bandi, G., Pahira, J., McGeagh, K. G., Collins, B. T., Krishnan, P., Dawson, N. A., Taylor, K. L., Dritschilo, A., Lynch, J. H., & Collins, S. P.
Venue
Radiation Oncology
Published
2013-03-13
Volume
8
Issue
1
Pages
58-58
ISSN
1748-717X (ISSN-L)
OpenAlex
W2164748078
Cited by
268
References
24
FWCI
24.36
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. https://app.cochat.ai/papers/10.1186/1748-717x-8-58
The paper
Chen, L. N., Suy, S., Uhm, S., Oermann, E. K., Ju, A. W., Chen, V., Hanscom, H. N., Laing, S., Kim, J. S., Lei, S., Batipps, G. P., Kowalczyk, K., Bandi, G., Pahira, J., McGeagh, K. G., Collins, B. T., Krishnan, P., Dawson, N. A., Taylor, K. L., . . . Collins, S. P. (2013). Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiation Oncology. https://doi.org/10.1186/1748-717x-8-58

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.